CD274 and cancer: A Phase I clinical trial (NCT03440437) for patients with advanced cancers and PD-L1 drug resistance initially showed that FS118 was well tolerated, but further studies are needed to determine the clinical benefit for patients refractory to anti-PD-(L)1 therapy [188].